Hung-Lin Chen
Papers
1
Total Citations
2
H-Index
1
About
Dr. Hung-Lin Chen is a urologic oncologist whose research centers on improving outcomes for prostate cancer patients, particularly through post-surgical management and biomarker-driven strategies. His most cited work investigates the efficacy of early dutasteride monotherapy in patients with detectable prostate-specific antigen (PSA) levels following robot-assisted radical prostatectomy (RARP). This retrospective analysis, spanning pathological stages T2a to T3b, addresses a critical clinical challenge: managing biochemical recurrence after surgery. By evaluating dutasteride’s role in suppressing PSA progression, Dr. Chen’s research contributes to personalized treatment pathways that may delay or avoid more aggressive interventions. While his citation count is currently modest, his work reflects a focused commitment to refining post-operative care in urologic oncology. Dr. Chen’s studies bridge surgical precision and pharmacological management, offering practical insights for clinicians navigating the complexities of prostate cancer surveillance. His ongoing contributions hold promise for enhancing long-term patient outcomes in the evolving landscape of robotic surgery and targeted therapies.
Research Focus
Key Achievements
Top Papers
- 1